J.P. Morgan analyst Anupam Rama has maintained their bullish stance on BBIO stock, giving a Buy rating on May 16.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Anupam Rama’s rating is based on the promising launch momentum of BridgeBio Pharma’s Attruby in the ATTR-CM treatment landscape. Despite a preference for Alnylam’s Amvuttra by some experts, Attruby is well-positioned due to its effectiveness in both naïve patients and those progressing on existing therapies like Pfizer’s Vyndaqel/Vyndamax.
Additionally, Anupam Rama highlights the underappreciated potential of BridgeBio’s pipeline, with pivotal readouts for other products anticipated in the near future. This combination of a strong product launch and a robust pipeline contributes to the Buy rating for BridgeBio Pharma’s stock.
In another report released on May 16, Bank of America Securities also maintained a Buy rating on the stock with a $50.00 price target.